Regulation - Research, Financial


Current filters:


Popular Filters

US global share of biomedical research spending declines, as Asia gains


The USA’s global share of biomedical research spending fell from 51% in 2007 to 45% in 2012, while…

Asia-PacificChinaFinancialNorth AmericaPharmaceuticalRegulationResearchUSA

Curis plunges on negative CUCD-427 news; 3rd-qtr loss down


Oncology focussed US biotech firm Curis saw its shares sink 21% to $3.08, after it revealed receipt of…

BiotechnologyCUCD-427CurisFinancialNorth AmericaOncologyRegulationResearch

The case for Insmed's CF drug candidate Arikace; analysts' views


The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth


At a meeting today with industry analysts, senior leaders from the Janssen pharmaceutical companies of…

FinancialJanssenJohnson & JohnsonPharmaceuticalRegulationResearch

Europe falling behind USA and China as attractive for life sciences sector


Intellectual property specialists Marks & Clerk's latest Life Sciences Report unveils the changing landscape…


Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone


Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Sinovac Biotech flu vaccine OKed in Mexico; EV71 results; financials


In what was a busy news day for Sinovac Biotech (Nasdaq: SVA), a leading provider of vaccines in China,…

BiotechnologyEV71FinancialRegulationResearchSinovac BiotechSouth America

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"


The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

Extraneous clinical data collection costs drug developers $4-$6 billion a year, says Tufts CSDD


One out of every five procedures performed during later stage clinical trials collects extraneous data…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulationResearch

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval


The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Medicines Australia sets up new taskforce on transparency for payments to doctors


Medicines Australia has invited the Australian Medical Association, the Royal Australian College of Physicians,…

Asia-PacificFinancialMarkets & MarketingPharmaceuticalRegulationResearch

US health care reform looks to squeeze players up and down the value chain


This summer's landmark Supreme Court decision to uphold the USA's Patient Privacy and Affordable Care…

BiotechnologyFinancialHealthcareNorth AmericaPharmaceuticalRegulationResearch

More guidelines needed to grow regenerative medicine market, report finds


Standardized research guidelines are needed to control and encourage the development of gene therapy…


Optimism and concerns of Netherlands' Biotech industry


Major trends and developments in the Dutch biotechnology sector, mainly based on the expectations voiced…


European governments must ensure R&D is converted into new businesses, new products


National governments in Europe need to do more to ensure that R&D innovation in the biotech industry…


ThromboGenics confident as it plans for ocriplasmin launch


Belgian biopharma firm ThromboGenics (Euronext Brussels: THR) says that, over the past 12 months, it…


GTx stock takes a pounding as FDA puts clinical hold on Capesaris trial


Tennessee, USA-based GTx (Nasdaq: GTXI) saw its shares plunge 30% to $3.98 earlier this week, after…

CapesarisFinancialGTxNorth AmericaOncologyPharmaceuticalRegulationResearch

Threats to US biomedical industry viewed by CEOs


Access to capital, a burdensome and uncertain regulatory environment and lack of innovation and productivity…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulationResearch

European Medicines Agency’s 2012 work program and budget


The European Medicines Agency’s Management Board, at its meeting on 15 December 15, adopted the…


Where to now for UK Life Sciences?


The 2012 UK Life Science Industry Leaders Survey* highlights a concern that the UK is losing its position…


Skyepharma updates on Exparel, Flutiform and financial position


UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Back to top